Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Tycel Phillips, Lu Chen, Tiffanie Barnhizer, Alex Herrera, Geoffrey Shouse, Daniel Ermann, Reem Karmali, Adam Kittai, Manali Kamdar, Diane Smith, James Godfrey, Brian Sworder, Swetha Thiruvengadam, John Baird, Avyakta Kallam, Elizabeth Budde, Alexey Danilov

Blood (2025) 146 (Supplement 1): 883.

https://doi.org/10.1182/blood-2025-883

Published: 2025

Journal Articles

Genomic and immune determinants of response to CD3 x CD20 bispecific antibodies in aggressive B-cell lymphoma

XI Yang, Weiwei Zhang, Anamarija Perry, Pinyu Hou, Winston Lee, James Godfrey, Yasmin Karimi, Joo Song

Blood (2025) 146 (Supplement 1): 3542.

https://doi.org/10.1182/blood-2025-3542

Published: 2025

Journal Articles

Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma

Karan Chohan, James Godfrey, Steven Bair, Lorenzo Falchi, Manali Kamdar, Ajay Major, Sonia Godbole, Gilles Salles, Omnia Farahat, Amy Ayers, Ayushi Chauhan, Alex Herrera, Geoffrey Shouse, Sairah Ahmed, Yazeed Sawalha

Blood (2025) 146 (Supplement 1): 5520.

https://doi.org/10.1182/blood-2025-5520

Published: 2025

Journal Articles

Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment naïve follicular lymphoma

Blood (2025) 146 (Supplement 1): 5373.

https://doi.org/10.1182/blood-2025-5373

Published: 2025

Journal Articles

Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas

Christina Poh, Jasmine Zain, James Godfrey, Christiane Querfeld, Lu Chen, Sandrine Puverel, Pamela Allen, Alex Herrera

Blood (2025) 146 (Supplement 1): 1861.

https://doi.org/10.1182/blood-2025-1861

Published: 2025

Journal Articles

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

Blood (2025) 146 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2025-6364

Published: 2025

Journal Articles

Transcriptional profiling refines DLBCL classification and identifies subtypes with distinct therapeutic vulnerabilities

James Godfrey, Sravya Tumuluru, Alan Cooper, Gilles Salles, Marek Trneny, Georg Lenz, Franck Morschhauser, Fabrice Jardin, Will Harris, Sandhya Balasubramanian, Matthew Sugidono, Connie Lee Batlevi, Yanwen Jiang, Justin Kline, Alex Herrera

Blood (2025) 146 (Supplement 1): 49.

https://doi.org/10.1182/blood-2025-49

Published: 2025

Journal Articles

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1742.1.

https://doi.org/10.1182/blood-2024-198727

Published: 2024

Journal Articles

A CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition

Alan Cooper, Sravya Tumuluru, Kyle Kissick, Girish Venkataraman, Joo Y Song, Andrew Lytle, Gerben Duns, Jovian Yu, Nikita Kotlov, Alexander Bagaev, Brendan Paul Hodkinson, Srimathi Srinivasan, Sonali M. Smith, David W. Scott, Christian Steidl, James Godfrey, Justin Kline

Blood (2023) 142 (Supplement 1): 851.

https://doi.org/10.1182/blood-2023-182390

Published: 2023

Journal Articles

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Blood (2023) 142 (16): 1359–1370.

https://doi.org/10.1182/blood.2023020485

Published: 2023

Includes: Supplemental data

Journal Articles

Prospective Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

Kirk Cahill, James Godfrey, Chadi Nabhan, Theodore G. Karrison, Jessica Robertson, Justin Kline, Kenneth S. Cohen, Michael R. Bishop, Walter M. Stadler, Reem Karmali, Parameswaran Venugopal, Seo-Hyun Kim, Aaron P. Rapoport, Sonali M. Smith

Blood (2022) 140 (Supplement 1): 6594–6595.

https://doi.org/10.1182/blood-2022-168444

Published: 2022

Journal Articles

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 1065–1067.

https://doi.org/10.1182/blood-2022-165699

Published: 2022

Journal Articles

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Blood (2022) 140 (Supplement 1): 1328–1331.

https://doi.org/10.1182/blood-2022-157829

Published: 2022

Journal Articles

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Matthew Mei, Joycelynne Palmer, Ni-Chun Tsai, Hun Ju Lee, Iris Isufi, Leslie L. Popplewell, Lynne Smith, Lacolle Peters, Lara Rodriguez, James Godfrey, John H. Baird, Joo Y. Song, Steven T. Rosen, Larry W. Kwak, Stephen J Forman, Alex F. Herrera

Blood (2022) 140 (Supplement 1): 774–776.

https://doi.org/10.1182/blood-2022-167626

Published: 2022

Journal Articles

Integrative Genomic Analysis Uncovers Unique Diffuse Large B Cell Lymphoma (DLBCL) Immune Environments and Identifies Associations with Specific Oncogenic Alterations

Sravya Tumuluru, James Godfrey, Jovian Yu, Alan Cooper, Xiufen Chen, Gerben Duns, Sonali M. Smith, Christian Steidl, Justin Kline

Blood (2021) 138 (Supplement 1): 449.

https://doi.org/10.1182/blood-2021-153724

Published: 2021

Journal Articles

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma

Jonathan A. Trujillo, James Godfrey, Yifei Hu, Jun Huang, Sonali M. Smith, Matthew J. Frigault, Zachariah DeFilipp, Daniel Appelbaum, Yonglin Pu, Nicholas Feinberg, Thomas Althaus, Michael R. Bishop, Peter A. Riedell, Justin Kline

Blood (2021) 137 (24): 3454–3459.

https://doi.org/10.1182/blood.2020009148

Published: 2021

Journal Articles

Macrophage Activation By Dual PI3K-δ/γ Inhibition Enhances Anti-CD47-Mediated Phagocytosis and Prolongs Survival in DLBCL

James Godfrey, MD, Wenjun Kang, MS, Lei Huang, PhD, Silvia Coma, PhD, Roy Maute, PhD, Mark P. Chao, MD PhD, Jonathan A Pachter, PhD, Sonali Smith, MD, Justin Kline, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-143304

Published: 2020

Journal Articles

Single-Cell Analysis of the Classical Hodgkin Lymphoma Immune Environment Reveals a Clonally-Expanded CD8 + T Cell Population with a Cytotoxic Phenotype

Jovian Yu, MD, Xiufen Chen, PhD, James Godfrey, MD, Girish Venkataraman, MD MBBS, Sonali M. Smith, MD, Mengjie Chen, PhD, Justin Kline, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-137171

Published: 2020

Journal Articles

The immune landscape and response to immune checkpoint blockade therapy in lymphoma

Justin Kline, James Godfrey, Stephen M. Ansell

Blood (2020) 135 (8): 523–533.

https://doi.org/10.1182/blood.2019000847

Published: 2020

Journal Articles

Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes

Michael Leukam, MDMS, James Godfrey, MD, Sravya Tumuluru, Girish Venkataraman, MD MBBS, Sonali M. Smith, MD, Riyue Bao, PhD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 924.

https://doi.org/10.1182/blood-2019-131562

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Genomic and immune determinants of response to CD3 x CD20 bispecific antibodies in aggressive B-cell lymphoma

Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma

Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment naïve follicular lymphoma

Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

Transcriptional profiling refines DLBCL classification and identifies subtypes with distinct therapeutic vulnerabilities

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Prospective Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Integrative Genomic Analysis Uncovers Unique Diffuse Large B Cell Lymphoma (DLBCL) Immune Environments and Identifies Associations with Specific Oncogenic Alterations

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma

Macrophage Activation By Dual PI3K-δ/γ Inhibition Enhances Anti-CD47-Mediated Phagocytosis and Prolongs Survival in DLBCL

Single-Cell Analysis of the Classical Hodgkin Lymphoma Immune Environment Reveals a Clonally-Expanded CD8 + T Cell Population with a Cytotoxic Phenotype

The immune landscape and response to immune checkpoint blockade therapy in lymphoma

Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only